文献速递肥胖与代谢综合征

定义氯卡色林减重反应的预测因素

Defining Predictors of Weight Loss Response to Lorcaserin.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

30名肥胖个体随机交叉接受7天安慰剂与氯卡色林,19人继续治疗6个月。氯卡色林使脑脊液POMC前激素降低、β-内啡肽升高30%(P < .001),并伴胰岛素、血糖及HOMA-IR下降;基线脑脊液POMC与减重呈负相关(P = .07),并识别出预测减重超过10%的脑脊液POMC切点值。

要点

  • 氯卡色林治疗7天使脑脊液POMC前激素降低、β-内啡肽升高30%(P < .001)。
  • 基线脑脊液POMC与减重呈负相关(P = .07),并识别出预测减重超过10%的切点值。
  • 脑脊液POMC的早期变化与血糖指标的改善平行,且不依赖于减重。

核心结论

  • 氯卡色林影响人脑黑色素皮质素系统,黑色素皮质素活性较低者效果更佳。
  • 脑脊液POMC早期变化与减重无关的血糖指标改善平行。
  • 评估黑色素皮质素活性或可为5HT2cR激动剂治疗肥胖的个体化用药提供途径。

研究设计与样本

  • 随机交叉研究:30名肥胖个体接受7天安慰剂与氯卡色林治疗,其中19人继续氯卡色林治疗6个月。
  • 测量脑脊液POMC肽以识别预测减重的潜在生物标志物,并研究胰岛素、瘦素及餐时食物摄入。

主要发现

  • 氯卡色林治疗7天后脑脊液POMC前激素显著降低、加工产物β-内啡肽升高,β-内啡肽/POMC比值增加30%(P < .001)。
  • 减重前伴随胰岛素、血糖及稳态模型评估胰岛素抵抗(HOMA-IR)大幅下降。
  • 6个月减重6.9%后脑脊液POMC肽变化持续存在,与既往单纯饮食后的报道不同。
  • POMC、食物摄入或其他激素的变化未预测减重;基线脑脊液POMC与减重呈负相关(P = .07)。
  • 识别出一个脑脊液POMC切点水平,可预测减重超过10%。

关键数值与推荐

  • β-内啡肽/POMC比值增加30%(P < .001)。
  • 6个月时减重6.9%。
  • 基线脑脊液POMC与减重负相关(P = .07)。
  • 识别出预测减重超过10%的脑脊液POMC切点水平(原文未写明具体数值)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Individual responses to weight loss (WL) medications vary widely and prediction of response remains elusive. OBJECTIVE: We investigated biomarkers associated with use of lorcaserin (LOR), a 5HT2cR agonist that targets proopiomelanocortin (POMC) neurons that regulate energy and glucose homeostasis, to identify predictors of clinical efficacy. METHODS: Thirty individuals with obesity were treated with 7 days of placebo and LOR in a randomized crossover study. Nineteen participants continued on LOR for 6 months. Cerebrospinal fluid (CSF) POMC peptide measurements were used to identify potential biomarkers that predict WL. Insulin, leptin, and food intake during a meal were also studied. RESULTS: LOR induced a significant decrease in CSF levels of the POMC prohormone and an increase in its processed peptide β-endorphin after 7 days; β-endorphin/POMC increased by 30% (P < .001). This was accompanied by a substantial decrease in insulin, glucose, and homeostasis model assessment of insulin resistance before WL. Changes in CSF POMC peptides persisted after WL (6.9%) at 6 months that were distinct from prior reports after diet alone. Changes in POMC, food intake, or other hormones did not predict WL. However, baseline CSF POMC correlated negatively with WL (P = .07) and a cutoff level of CSF POMC was identified that predicted more than 10% WL. CONCLUSION: Our results provide evidence that LOR affects the brain melanocortin system in humans and that effectiveness is increased in individuals with lower melanocortin activity. Furthermore, early changes in CSF POMC parallel WL-independent improvements in glycemic indexes. Thus, assessment of melanocortin activity could provide a way to personalize pharmacotherapy of obesity with 5HT2cR agonists.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sideri Gugger A, Dimino C, Panigrahi SK, et al. Defining Predictors of Weight Loss Response to Lorcaserin. J Clin Endocrinol Metab. 2023. PMID: 36897161. doi:10.1210/clinem/dgad139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。